Insmed (INSM) Total Non-Current Liabilities (2010 - 2026)
Insmed (INSM) recorded quarterly Total Non-Current Liabilities of $1.4 billion in Q1 2026, up 12.72% quarter-over-quarter from $1.2 billion in Q4 2025, and down 9.96% on a YoY basis from $1.5 billion in Q1 2025.
Insmed (INSM) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Insmed's Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $1.4 billion for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 9.96% year-over-year to $1.4 billion; the TTM figure through Mar 2026 stood at $1.4 billion (down 9.96% YoY), while the FY2025 annual figure was $1.2 billion, down 22.9% from the prior year.
- Total Non-Current Liabilities was $1.4 billion for Q1 2026 at Insmed, up from $1.2 billion in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $1.8 billion in Q2 2024 to a low of $953.5 million in Q2 2022.
- Historically, Total Non-Current Liabilities has averaged $1.4 billion across 5 years, with a median of $1.5 billion in 2025.
- The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities jumped 106.12% in 2022, then plunged 30.38% in 2025.
- A 5-year view of Total Non-Current Liabilities shows it stood at $1.6 billion in 2022, then climbed by 1.03% to $1.6 billion in 2023, then declined by 0.39% to $1.6 billion in 2024, then declined by 22.9% to $1.2 billion in 2025, then climbed by 12.72% to $1.4 billion in 2026.
- The last three Total Non-Current Liabilities figures came in at $1.4 billion (Q1 2026), $1.2 billion (Q4 2025), and $1.4 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 42,980.09 |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 64.76 Mn |
| 10 | Insmed | 19.79 Bn | 18.57 Bn | 258.54 Mn | 1.37 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.37 Bn |
| Dec 31, 2025 | 1.21 Bn |
| Sep 30, 2025 | 1.41 Bn |
| Jun 30, 2025 | 1.22 Bn |
| Mar 31, 2025 | 1.52 Bn |
| Dec 31, 2024 | 1.57 Bn |
| Sep 30, 2024 | 1.57 Bn |
| Jun 30, 2024 | 1.76 Bn |
| Mar 31, 2024 | 1.55 Bn |
| Dec 31, 2023 | 1.58 Bn |
| Sep 30, 2023 | 1.54 Bn |
| Jun 30, 2023 | 1.53 Bn |
| Mar 31, 2023 | 1.51 Bn |
| Dec 31, 2022 | 1.56 Bn |
| Sep 30, 2022 | 965.48 Mn |
| Jun 30, 2022 | 953.51 Mn |
| Mar 31, 2022 | 967.32 Mn |
| Dec 31, 2021 | 757.37 Mn |
| Sep 30, 2021 | 783.05 Mn |
| Jun 30, 2021 | 685.92 Mn |